

Board of Directors (as of June 20, 2025)

Yuji Takada
Outside Director Audit &
Supervisory Committee
Member



Taisuke Fujita
Representative Director, Executive
Vice President, Chief Financial
Officer (CFO)



Hideki Kawakubo
Representative Director,
President, and Chief Executive
Officer (CEO)



Katsusuke Higuchi
Outside Director Audit &
Supervisory Committee Member



Mime Egami
Outside Director Audit &
Supervisory Committee Member



James B. Rosenwald III
Outside Director



New

Skills Matrix

		Main position	Committee		Skills and areas of expertise that are particularly expected				
			Nominating Committee	Compensation Committee	Corporate management	Medical industry	Overseas business	Governance, risk management	Finance, accounting
Directors	Hideki Kawakubo	Representative Director, President, and Chief Executive Officer (CEO)			●	●		●	●
	Taisuke Fujita	Representative Director, Executive Vice President, Chief Financial Officer (CFO)	●	●	●		●		●
	James B. Rosenwald III	Outside Director	●	●	●				
	Katsusuke Higuchi	Outside Director Audit & Supervisory Committee Member [Independent Director]	●	●				●	●
	Yuji Takada	Outside Director Audit & Supervisory Committee Member [Independent Director]	Chairperson	●				●	
	Mime Egami	Outside Director Audit & Supervisory Committee Member [Independent Director]	●	Chairperson	●	●	●	●	

Note: The above table shows skills and areas of expertise that are particularly expected of each director and does not represent all of the skills and areas of expertise of each director.

Executive Officers (as of July 1, 2025)

		Main position
Executive officers	Go Ohashi	Senior Executive Officer Chief Production Officer (CPO) and General Manager of Production Div. President and Director of PT. HOGY INDONESIA
	Yoshinori Mochizuki	Executive Officer General Manager of Manufacturing Dept., Production Div.
	Taichiro Seike	Executive Officer General Manager of Overseas Business Development Dept.
	Yoshihiko Tenbo	Executive Officer General Manager of Corporate Strategy Dept., Business Administration Div.
	Morihide Tabata	Executive Officer General Manager of Procurement Dept., Business Administration Div.
	Keijiyo Asayama	Executive Officer General Manager of Quality and Regulatory Affairs Div. and General Manager of Quality Assurance Dept.
	Ko Ishikawa	Executive Officer General Manager of Research and Development Div.
	Suguru Kinoshita	Executive Officer General Manager of East Japan Sales Dept., Sales Function, Commercial Div.
	Takayuki Ebara	Executive Officer General Manager of West Japan Sales Dept., Sales Function, Commercial Div.
	Hiroyuki Yoshidome	Executive Officer General Manager of Marketing Function, Commercial Div.

Outside Board Members

Outside Director Audit & Supervisory Committee Member

Katsusuke Higuchi

◆Career summary

Dec. 2005 Joined ChuoAoyama Audit Corporation
Jul. 2006 Joined PricewaterhouseCoopers Aarata
(currently PricewaterhouseCoopers Japan LLC)
Jul. 2009 Registered as Certified Public Accountant
Jul. 2010 Joined PricewaterhouseCoopers Co., Ltd.
(currently PwC Consulting LLC)
Jan. 2014 Representative Director of Higuchi Katsusuke CPA Firm
(present position)
June 2014 Registered as a tax accountant
June 2016 Representative Director of Suji-wa Mikata Co.,
Ltd. (present position)
June 2024 Outside Director of the Company
(Audit & Supervisory Committee Member)
(present position)



◆Reason for nomination

The Company has determined that Mr. Katsusuke Higuchi is familiar with corporate accounting as a certified public accountant, that he has ample insight related to the governance of corporate management, and that he can leverage his accounting knowledge, which has been fostered through his service as a certified public accountant, and accordingly it proposes that he be nominated as an outside director. Furthermore, as he satisfy the requirements for independent officers as provided for by the Tokyo Stock Exchange, we have determined that no conflict of interest exists with general shareholders and have designated him as an independent officer.

Outside Director Audit & Supervisory Committee Member

Yuji Takada

◆Career summary

Oct. 2003 Registered as an attorney-at-law
Joined MOMO-O, MATSUO & NAMBA
Dec. 2004 Joined Nagashima Ohno & Tsunematsu
Aug. 2013 Joined Shimada Hamba & Osajima
Jan. 2015 Partner at Shimada Hamba & Osajima
(present position)
Dec. 2018 Outside Director (Audit & Supervisory
Committee Member) of FreakOut Holdings,
Inc. (present position)
June 2023 Outside Corporate Auditor of the Company
(present position)
June 2024 Outside Director of the Company (Audit &
Supervisory Committee Member) (present
position)



◆Reason for nomination

The Company has determined that Mr. Yuji Takada is familiar with corporate legal affairs as an attorney-at-law, that he has ample insight related to the governance of corporate management, and that he can leverage his legal knowledge, which has been fostered through his service as an attorney-at-law, and accordingly it proposes that he be nominated as an outside director. Furthermore, as he satisfy the requirements for independent officers as provided for by the Tokyo Stock Exchange, we have determined that no conflict of interest exists with general shareholders and have designated him as an independent officer.

Outside Director Audit & Supervisory Committee Member

Mime Egami

◆Career summary

Apr. 1981 Joined The Mitsubishi Bank, Limited
(currently MUFG Bank, Ltd.)
Nov. 1984 Joined Citibank N.A., Tokyo Branch, Capital
Markets Division
Apr. 1992 Joined CIBC Wood Gundy (currently CIBC
Securities Inc.) Tokyo Branch, General Manager
of Capital Markets Dept.
Nov. 1998 Joined ABN AMRO Bank, Tokyo Branch, General
Manager of Health Care Dept., Corporate
Finance Div.
Nov. 2005 Visiting Professor, School of Medicine,
Tohoku University
Aug. 2006 Visiting Professor, Institute of Advanced
Biomedical Engineering and Science, Tokyo
Women's Medical University
Oct. 2015 Auditor, New Energy and Industrial Technology
Development Organization
Oct. 2015 Adjunct Professor, Pharmaceuticals and
Pharmaceutical Chemistry, University of Utah
(present position)
Mar. 2017 Established Organization of Cell Sheet Tissue
Engineering Regenerative Medicine Initiative,
Executive for Operations (present position)
June 2023 Outside Director of OBIC Co., Ltd.
(present position)
June 2024 Outside Director of the Company
(Audit & Supervisory Committee Member)
(present position)



◆Reason for nomination

The Company has determined that Ms. Mime Egami is well versed in international finance and advanced medical related technology, that she has ample insight related to the governance of corporate management that she gained through her experience of being an auditor, and that she will be able to utilize the knowledge, and accordingly it proposes that she be nominated as an outside director. Furthermore, as she satisfy the requirements for independent officers as provided for by the Tokyo Stock Exchange, we have determined that no conflict of interest exists with general shareholders and have designated her as an independent officer.

Outside Director

James B. Rosenwald III

◆Career summary

1981 Oliver R. Grace & Family, Senior Investment
Advisor/Portfolio Manager
1984 Rosenwald Capital Management, Inc., Founder,
Chairman and Chief Executive Officer (current)
1996 Beach Front Properties LLC, Co-Founder,
Managing Partner (current)
1999 Dalton Investments LLC, Co-Founder, Chief
Investment Officer (current)
2012 New York University, Adjunct Professor, Leonard
N. Stern School of Business (current)
2019 Rising Sun Management Ltd., Chief Investment
Officer (current)
2025 Director of the Company (present position)




◆Reason for nomination

The Company has determined that, Mr. James B. Rosenwald III, with his many years of experience from the perspectives of investment, management, and capital market governance, he can contribute to further strengthening the supervisory function of the Company's management from a standpoint different from that of the three Independent Outside Directors (Audit & Supervisory Committee Members) who currently serve on the Board of Directors, and accordingly it proposes that he be nominated as an outside director.

Network / Corporate Profile / Status of Shares

Network (as of April 1, 2025)



Corporate Profile (as of March 31, 2025)

Corporate name:

HOGY MEDICAL CO., LTD

Head office:

19F AKSAKA GREEN CROSS, 2-4-6,
Akasaka, Minato-ku, Tokyo 107-8615

Phone: +(81)3-6229-1300

<https://www.hogy.co.jp/english/>

Incorporated: April 3, 1961

Paid-in capital: ¥7,123 million

Number of employees:

1,409 (Consolidated),

748 (non-consolidated)

Listing:

Prime Market, Tokyo Stock Exchange

Code number: 3593

Financial year:

April 1 to March 31

Annual general meeting: Every June

Transfer agent:

Mitsubishi UFJ Trust and Banking
Corporation

Independent auditor:

Ernst & Young ShinNihon LLC

Status of Shares (as of March 31, 2025)

Total number of authorized shares:

130,000,000


Shares of common stock issued and outstanding:

22,535,463

Number of shareholders:

6,898

Shareholder Composition (Shareholding ratio)



Major Shareholders (Top 10)

Shareholders' names	Number of shares	Percentage of total (%)
The Master Trust Bank of Japan, Ltd. (Trust Account)	3,487,800	15.47
NIPPON ACTIVE VALUE FUND PLC	1,883,700	8.35
STATE STREET BANK AND TRUST COMPANY 505025	1,572,900	6.97
STATE STREET BANK AND TRUST COMPANY 505012	1,282,300	5.69
STATE STREET BANK AND TRUST COMPANY 505103	1,005,506	4.46
STATE STREET BANK AND TRUST COMPANY 505001	974,062	4.32
Custody Bank of Japan, Ltd. (Trust Account)	751,100	3.33
MEDIPAL HOLDINGS CORPORATION	584,000	2.59
NAVF SELECT LLC	580,600	2.57
THE BANK OF NEW YORK - JASDECTREATY ACCOUNT	571,300	2.53

Our company owns 975,631 treasury stock.